CD274 and neoplasm: If the tumor has CPS ≥10, it was considered PD-L1+ and this subset of patient is eligible for pembrolizumab, whereas in the TORCHLIGHT study, PD-L1+ was defined as JS311 CPS >1 and this subset of patients could benefit from toripalimab.